Cancer Watch - Keeping up to date with the latest cancer news and developments throughout the world. Beating cancer one tweet at a time.........................
Joined October 2019
- Tweets993
- Following148
- Followers76
- Likes2.7K
Cancer Watch retweeted
Could a facial photograph predict cancer survival?
FAHR-Face uses AI to estimate biological age and survival risk from facial images. Promising but needs prospective validation.
@pash22 @LancetDigitalH @OncoAlert @Dr_RayMak @HugoAerts
thelancet.com/journals/landi…
Cancer Watch retweeted
During a severe #Chemotherapy shortage, more than 1 in 4 carboplatin allocation decisions at a multisite health system were not aligned with policy intent, chiefly because of incomplete documentation.
ja.ma/4sbnggj
ALT A Sankey diagram displaying data flow across three columns. The left column shows categories 1-5 and Missing. The middle column divides into Received carboplatin and Did not receive carboplatin. The right column shows outcomes I-V.
Cancer Watch retweeted
🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯
#BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866
#ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS
#KidneyCancer: LITESPARK-011 & -012, ivonescimab, PE-PE, SWOG S2200, XmAb819
Our Participating Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger , @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi , @AmandaNizamMD, @drenriquegrande, @nataliagandur
@AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun , @ravikanesvaran , @BraunMDPhD, @EfstathiouEleni, @mzugman , @crisbergerot, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas , @sonpavde , @Dr_Oncologista
Cancer Watch retweeted
🆕 Article in press: Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial
🔗 Read it here: doi.org/10.1016/j.annonc.202…
Cancer Watch retweeted
At CCF, we know that every person who has shaped our community is so, so much more than their cholangiocarcinoma diagnosis. Help us remember them by creating a memorial post for your loved one on our In Memoriam page at curecca.org/in-memoriam. 💚
And be sure to access Legacy Caregiver resources, support, and opportunities to be involved at curecca.org/bereaved-support
Cancer Watch retweeted
A week before #ESMO26, #daraxonrasib receives EU approval for metastatic pancreatic cancer.....What next for UK access?
@PanCanResearch @PancreaticCanUK @BMJOncology @pash22 @EileenMOReilly @VivekSubbiah @MRitchieSD @OncoAlert @emahase_ @andrewgregory
ema.europa.eu/en/news/ema-re…
Cancer Watch retweeted
For patients with #RenalCellCarcinoma and #InferiorVenaCava tumor thrombus, neoadjuvant #StereotacticAblativeRadiotherapy before surgery appeared feasible, with no 90-day mortality or grade 4-5 radiation toxicities.
ja.ma/4ys68o7
Cancer Watch retweeted
A week before #ESMO26, #daraxonrasib receives EU approval for metastatic pancreatic cancer.....What next for UK access?
@PanCanResearch @PancreaticCanUK @BMJOncology @pash22 @EileenMOReilly @VivekSubbiah @MRitchieSD @OncoAlert @emahase_ @andrewgregory
ema.europa.eu/en/news/ema-re…
A week before #ESMO26, #daraxonrasib receives EU approval for metastatic pancreatic cancer.....What next for UK access?
@PanCanResearch @PancreaticCanUK @BMJOncology @pash22 @EileenMOReilly @VivekSubbiah @MRitchieSD @OncoAlert @emahase_ @andrewgregory
ema.europa.eu/en/news/ema-re…
Cancer Watch retweeted
Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911
Read the article. bit.ly/3VGspka
#BreastCancer #bcsm
Cancer Watch retweeted
Fantastic resource!
Free Access: My 2026 update on diagnosis, risk stratification, treatment, and prognosis of multiple myeloma.
Link: onlinelibrary.wiley.com/doi/… @AjHematology
Algorithms. 10 Tables!
Bookmark!
Cancer Watch retweeted
Living with lung cancer isn’t only physical. 💛 Your feelings are valid, scan-day dread and good days alike. Swipe for small ways to look after yourself, then tell us: what helps you?
#EmotionalWellnessMonth #ROS1 #rarecancer #Lungcancerawareness #Lungcancercommunity
Cancer Watch retweeted
Discover the collaborations, initiatives and expert discussions shaping the present and future of oncology. From innovation to clinical practice, from policy to patient-centred care, these sessions highlight progress across the #CancerCare continuum.
➡️ow.ly/Y2Qj50ZXbWO
#ESMO26
Cancer Watch retweeted
We are deeply saddened by the passing of Dr. Rachna Shroff at the age of 47 due to cancer.
Her contributions to oncology, especialy gasteointestinal cancers, will always live on.
medicine.arizona.edu/news/20…
Cancer Watch retweeted
🇯🇵 Japan's Ministry of Health, Labor and Welfare has recently approved subcutaneous pembrolizumab and berahyaluronidase for across all indications for which IV pembrolizumab is approved in Japan
Full details ➡️: hubs.li/Q04B5mYP0
#oncology
Cancer Watch retweeted
Ahead of #ESMO26, #CancerVaccines are generating global attention, but what questions still need answering before they can reshape #ClinicalPractice?
Read more in an interview with James Larkin, ESMO Congress 2026 Scientific Co-Chair 🔗 ow.ly/Hzug50ZXEg9
#InsightsbyESMO
Cancer Watch retweeted
Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up. ja.ma/4jeZsFT
Cancer Watch retweeted
💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring.
ja.ma/4B1XcrR
Cancer Watch retweeted
Colorectal cancer develops within a complex tumour microenvironment where the composition and activity of immune cells critically influence tumour progression and therapeutic response
bmjoncology.bmj.com/content/…
Cancer Watch retweeted
Not all KRAS mutations respond equally in #PDAC!
#Daraxonrasib overall ORR of 33%, but striking differences emerged by KRAS subtype:
🟢 G12V: 50%
🟡 G12D: 24%
🔴 G12R: 7% (vs 14% with chemotherapy!)
Pan-KRAS inhibition ≠ pan-KRAS efficacy.
fiercepharma.com/pharma/fda-…
